• LAST PRICE
    8.2150
  • TODAY'S CHANGE (%)
    Trending Down-0.0350 (-0.4242%)
  • Bid / Lots
    8.2000/ 9
  • Ask / Lots
    8.2300/ 6
  • Open / Previous Close
    8.2200 / 8.2500
  • Day Range
    Low 7.9900
    High 8.3900
  • 52 Week Range
    Low 1.5200
    High 11.2500
  • Volume
    248,407
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 8.25
TimeVolumeSMMT
09:32 ET274188.15
09:34 ET157118.03
09:36 ET8008.1099
09:38 ET89128.2
09:39 ET278848.3
09:41 ET130758.29
09:43 ET48188.275
09:45 ET106508.27
09:48 ET51008.315
09:50 ET68648.25
09:52 ET29348.29
09:54 ET36758.305
09:56 ET74098.27
09:57 ET53788.16
09:59 ET51148.21
10:01 ET107508.32
10:03 ET7508.29
10:06 ET60078.235
10:08 ET89428.31
10:10 ET94918.3464
10:12 ET18098.23
10:14 ET25008.31
10:15 ET114448.22
10:17 ET64378.22
10:19 ET32588.24
10:21 ET36998.215
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSMMT
Summit Therapeutics Inc
5.3B
-49.6x
---
United StatesNUVL
Nuvalent Inc
5.1B
-33.2x
---
United StatesBBIO
BridgeBio Pharma Inc
5.1B
-9.0x
---
United StatesVKTX
Viking Therapeutics Inc
5.8B
-56.2x
---
United StatesKRYS
Krystal Biotech Inc
5.1B
98.9x
---
United StatesMDGL
Madrigal Pharmaceuticals Inc
6.2B
-12.4x
---
As of 2024-06-13

Company Information

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Contact Information

Headquarters
2882 Sand Hill Road, Suite 106MENLO PARK, CA, United States 94025
Phone
650-460-8308
Fax
302-655-5049

Executives

Executive Chairman of the Board, Co-Chief Executive Officer
Robert Duggan
President, Co-Chief Executive Officer, Director
Mahkam Zanganeh
Chief Financial Officer
Ankur Dhingra
Chief Operating Officer, Director
Manmeet Soni
Lead Non-Executive Independent Director
Kenneth Clark

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.3B
Revenue (TTM)
$0.00
Shares Outstanding
702.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.96
EPS
$-0.17
Book Value
$0.11
P/E Ratio
-49.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.